Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonel Trebicka

Showing results (411-420 of 512) with videos related to

Pageof 52
Sort By:
Frontiers in Physiology|September 7, 2021
Extrahepatic Surgery in Cirrhosis Significantly Increases Portal Pressure in Preclinical Animal ModelsJohannes Chang, Jonathan Meinke, Moritz Geck, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|May 27, 2026
A HDL-based cirrhosis risk score improves the prediction of short-term mortality in acutely decompensated cirrhosisRudolf E Stauber, Eva M Usón-Raposo, Florian Rainer, et al.
JHEP Reports : Innovation in Hepatology|April 29, 2024
Soluble urokinase plasminogen activator receptor levels predict survival in patients with portal hypertension undergoing TIPSSven H Loosen, Fabian Benz, Raphael Mohr, et al.
Cell Death & Disease|August 29, 2025
Correction: Macrophages downregulate NEDD9 to counteract S. Typhimurium- mediated FAK-AKT activation and lysosome inhibitionJulia Fischer, Lisa Rusyn, Frederike Krus, et al.
Cell Death & Disease|June 12, 2025
Macrophages downregulate NEDD9 to counteract S. Typhimurium- mediated FAK-AKT activation and lysosome inhibitionJulia Fischer, Lisa Rusyn, Frederike Krus, et al.
Annals of Internal Medicine|August 5, 2009
Etiology, management, and outcome of the Budd-Chiari syndromeSarwa Darwish Murad, Aurelie Plessier, Manuel Hernandez-Guerra, et al.
Hepatology (Baltimore, Md.)|August 22, 2022
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosisSandra Torres, Cristina Ortiz, Nadine Bachtler, et al.
Alimentary Pharmacology & Therapeutics|June 8, 2020
A prospective, multicentre study in acute non-cirrhotic, non-malignant portal vein thrombosis: comparison of medical and interventional treatmentMartin Rössle, Dominik Bettinger, Jonel Trebicka, et al.
Hepatology (Baltimore, Md.)|March 13, 2014
Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosisMichaela Granzow, Robert Schierwagen, Sabine Klein, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 26, 2016
Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosisAndrea De Gottardi, Jonel Trebicka, Christoph Klinger, et al.
Pageof 52

Showing results (411-420 of 512) with videos related to

Sort By:
Pageof 52
Frontiers in Physiology|September 7, 2021
Extrahepatic Surgery in Cirrhosis Significantly Increases Portal Pressure in Preclinical Animal ModelsJohannes Chang, Jonathan Meinke, Moritz Geck, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|May 27, 2026
A HDL-based cirrhosis risk score improves the prediction of short-term mortality in acutely decompensated cirrhosisRudolf E Stauber, Eva M Usón-Raposo, Florian Rainer, et al.
JHEP Reports : Innovation in Hepatology|April 29, 2024
Soluble urokinase plasminogen activator receptor levels predict survival in patients with portal hypertension undergoing TIPSSven H Loosen, Fabian Benz, Raphael Mohr, et al.
Cell Death & Disease|August 29, 2025
Correction: Macrophages downregulate NEDD9 to counteract S. Typhimurium- mediated FAK-AKT activation and lysosome inhibitionJulia Fischer, Lisa Rusyn, Frederike Krus, et al.
Cell Death & Disease|June 12, 2025
Macrophages downregulate NEDD9 to counteract S. Typhimurium- mediated FAK-AKT activation and lysosome inhibitionJulia Fischer, Lisa Rusyn, Frederike Krus, et al.
Annals of Internal Medicine|August 5, 2009
Etiology, management, and outcome of the Budd-Chiari syndromeSarwa Darwish Murad, Aurelie Plessier, Manuel Hernandez-Guerra, et al.
Hepatology (Baltimore, Md.)|August 22, 2022
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosisSandra Torres, Cristina Ortiz, Nadine Bachtler, et al.
Alimentary Pharmacology & Therapeutics|June 8, 2020
A prospective, multicentre study in acute non-cirrhotic, non-malignant portal vein thrombosis: comparison of medical and interventional treatmentMartin Rössle, Dominik Bettinger, Jonel Trebicka, et al.
Hepatology (Baltimore, Md.)|March 13, 2014
Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosisMichaela Granzow, Robert Schierwagen, Sabine Klein, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 26, 2016
Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosisAndrea De Gottardi, Jonel Trebicka, Christoph Klinger, et al.
Pageof 52